2017, Document, Informed consent and Presentation

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2017

Document

Informed consent

Presentation

Analysis of U.S. Food and Drug Administration Draft Guidance on Clinical Trials with Psychedelic Drugs

Healthcare Law Insights blog

JUNE 30, 2023

Food and Drug Administration (FDA) published a draft guidance document with foundational considerations for researchers that are developing psychedelic drugs for the treatment of medical conditions. The document frequently refers readers to existing guidance while noting key considerations that are unique to psychedelic drugs in each section.

Document

Document Informed consent 2003 2010

Undisclosed Conflicts of Interest by Physicians Creating the CDC Opioid Prescribing Guidelines: Bad Faith or Incompetence?

Pallimed

SEPTEMBER 12, 2022

WLF’s complaint compelled the CDC to re-open a second open comment period for the public, lasting 30 days in duration, rather than the two-day period for comment which CDC had originally presented via a September 2015 webinar (4, 35). Presented on February 10, 2022, for the Annual Assembly of Hospice and Palliative Care (Virtual Conference).

2016

2016 2019 2022 2015

Home Care & Hospice Network

Analysis of U.S. Food and Drug Administration Draft Guidance on Clinical Trials with Psychedelic Drugs

Undisclosed Conflicts of Interest by Physicians Creating the CDC Opioid Prescribing Guidelines: Bad Faith or Incompetence?

Stay Connected